MyoKardia, Inc. (MYOK): Price and Financial Metrics


MyoKardia, Inc. (MYOK)

Today's Latest Price: $222.76 USD

0.15 (-0.07%)

Updated Oct 28 10:19am

Add MYOK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MYOK Stock Summary

  • MYOK's price/sales ratio is 283.62; that's higher than the P/S ratio of 98.98% of US stocks.
  • Over the past twelve months, MYOK has reported earnings growth of 292.69%, putting it ahead of 95.71% of US stocks in our set.
  • As for revenue growth, note that MYOK's revenue has grown -53.7% over the past 12 months; that beats the revenue growth of merely 3.04% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI.
  • Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com.

MYOK Stock Price Chart Interactive Chart >

Price chart for MYOK

MYOK Price/Volume Stats

Current price $222.76 52-week high $224.00
Prev. close $222.91 52-week low $42.65
Day low $222.75 Volume 121,098
Day high $222.95 Avg. volume 716,766
50-day MA $156.31 Dividend yield N/A
200-day MA $98.31 Market Cap 11.81B

MyoKardia, Inc. (MYOK) Company Bio


MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases


MYOK Latest News Stream


Event/Time News Detail
Loading, please wait...

MYOK Latest Social Stream


Loading social stream, please wait...

View Full MYOK Social Stream

Latest MYOK News From Around the Web

Below are the latest news stories about MyoKardia Inc that investors may wish to consider to help them evaluate MYOK as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

MyoKardia (MYOK) Investor Presentation - Slideshow

The following slide deck was published by MyoKardia, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and…

GlobeNewswire | July 28, 2020

Hypertrophic Cardiomyopathy Pipeline 2020 Featuring Algomedix, Celltrion, MyoKardia, Novartis and 4 Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hypertrophic Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypertrophic Cardiomyopathy is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline's potential. Development of Hypertrophic Cardiomyopathy medicines is identified as integral to the strateg

Business Wire | July 27, 2020

Read More 'MYOK' Stories Here

MYOK Price Returns

1-mo 66.36%
3-mo 135.18%
6-mo 291.43%
1-year 287.14%
3-year 489.31%
5-year 2,081.78%
YTD 205.63%
2019 49.17%
2018 16.06%
2017 225.10%
2016 -11.66%
2015 N/A

Continue Researching MYOK

Here are a few links from around the web to help you further your research on MyoKardia Inc's stock as an investment opportunity:

MyoKardia Inc (MYOK) Stock Price | Nasdaq
MyoKardia Inc (MYOK) Stock Quote, History and News - Yahoo Finance
MyoKardia Inc (MYOK) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8625 seconds.